2Xideas AG Trims Stock Position in IQVIA Holdings Inc. $IQV

2Xideas AG decreased its position in shares of IQVIA Holdings Inc. (NYSE:IQV) by 69.2% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 62,894 shares of the medical research company’s stock after selling 141,343 shares during the quarter. IQVIA makes up about 1.7% of 2Xideas AG’s holdings, making the stock its 14th largest position. 2Xideas AG’s holdings in IQVIA were worth $9,911,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also made changes to their positions in IQV. Clal Insurance Enterprises Holdings Ltd grew its stake in IQVIA by 436.7% during the 1st quarter. Clal Insurance Enterprises Holdings Ltd now owns 161 shares of the medical research company’s stock worth $28,000 after buying an additional 131 shares during the last quarter. Trust Co. of Toledo NA OH acquired a new stake in shares of IQVIA in the second quarter valued at approximately $39,000. J.Safra Asset Management Corp grew its position in shares of IQVIA by 208.6% during the second quarter. J.Safra Asset Management Corp now owns 250 shares of the medical research company’s stock worth $39,000 after acquiring an additional 169 shares during the last quarter. Rothschild Investment LLC increased its holdings in shares of IQVIA by 85.5% in the 2nd quarter. Rothschild Investment LLC now owns 269 shares of the medical research company’s stock valued at $42,000 after acquiring an additional 124 shares during the period. Finally, NewSquare Capital LLC boosted its stake in IQVIA by 185.3% during the 2nd quarter. NewSquare Capital LLC now owns 291 shares of the medical research company’s stock worth $46,000 after purchasing an additional 189 shares during the period. 89.62% of the stock is owned by hedge funds and other institutional investors.

IQVIA Price Performance

Shares of NYSE:IQV opened at $223.66 on Tuesday. IQVIA Holdings Inc. has a 12 month low of $134.65 and a 12 month high of $234.29. The firm has a market capitalization of $38.09 billion, a price-to-earnings ratio of 30.68, a price-to-earnings-growth ratio of 2.53 and a beta of 1.37. The business’s 50 day simple moving average is $215.33 and its 200-day simple moving average is $187.66. The company has a debt-to-equity ratio of 2.03, a current ratio of 0.70 and a quick ratio of 0.70.

IQVIA (NYSE:IQV) last posted its earnings results on Tuesday, October 28th. The medical research company reported $3.00 earnings per share for the quarter, beating the consensus estimate of $2.98 by $0.02. IQVIA had a return on equity of 30.70% and a net margin of 8.07%.The company had revenue of $4.10 billion for the quarter, compared to analyst estimates of $4.07 billion. During the same quarter in the prior year, the company earned $2.84 earnings per share. IQVIA’s revenue was up 5.2% compared to the same quarter last year. IQVIA has set its FY 2025 guidance at 11.850-11.950 EPS. As a group, equities analysts forecast that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts have commented on IQV shares. Evercore ISI lifted their price objective on shares of IQVIA from $220.00 to $240.00 and gave the company an “outperform” rating in a research note on Wednesday, October 8th. TD Cowen downgraded IQVIA from a “buy” rating to a “hold” rating and upped their price objective for the company from $206.00 to $215.00 in a research note on Monday, November 3rd. JPMorgan Chase & Co. increased their price objective on IQVIA from $177.00 to $255.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 29th. Robert W. Baird set a $258.00 price target on IQVIA and gave the stock an “outperform” rating in a research note on Wednesday, October 29th. Finally, Stifel Nicolaus lifted their price objective on shares of IQVIA from $234.00 to $254.00 and gave the company a “buy” rating in a research report on Wednesday, October 29th. Two analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and six have assigned a Hold rating to the stock. According to MarketBeat, IQVIA has an average rating of “Moderate Buy” and an average price target of $241.44.

Insider Activity

In related news, insider Eric Sherbet sold 4,000 shares of the company’s stock in a transaction that occurred on Wednesday, October 29th. The stock was sold at an average price of $219.70, for a total value of $878,800.00. Following the sale, the insider owned 27,108 shares of the company’s stock, valued at approximately $5,955,627.60. This represents a 12.86% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 1.60% of the stock is owned by corporate insiders.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.